Regeneron Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0R2M.L | 068270.KS | BIIB | 9995.HK | BHVN | 214450.KQ | |
|---|---|---|---|---|---|---|
| Market cap | — | 49.02T | 37.61B | 40.23B | 2.30B | 2.34T |
| P/E (TTM) | 13.3 | — | 110.2 | 6.1 | — | — |
| Forward P/E | — | — | 15.6 | 46.7 | -8.2 | — |
| Price/book | 2.8 | — | 2.0 | 3.8 | -23.4 | — |
| Dividend yield | 0.39% | 0.36% | — | — | — | 1.66% |
| 1-year change | +45.51% | +20.07% | +62.35% | −19.94% | +78.66% | −56.00% |
| Today | −1.80% | +7.50% | +2.22% | +1.49% | −2.37% | +0.67% |
The closest companies by business. Prices may be delayed up to 20 min.
Latest news
All 0R2M.L news ›Regeneron Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
(NASDAQ:REGN) 2026-11-03 Seeking Alpha The following slide deck was published by Regeneron Pharmaceuticals, Inc. in conjunction with their 2026 Q3 earnings call. Q3: 2026-10-30 Earnings Summary
More from 1 other outlet
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Boost from Truist Financial
MarketBeat Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Boost from Truist Financial - Truist Financial raised Regeneron’s price target from $780 to $982 and maintained a “buy” rating. Othe
Bernstein maintains Regeneron Pharmaceuticals at Market Perform, raises price target to $812 from $756
TradingView Bernstein maintained Regeneron Pharmaceuticals at Market Perform and raised its price target to $812 from $756, a 7.4% increase. The price target implies a downside of 12.5% from the Oc
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $997.00 Price Target at Leerink Partners
MarketBeat Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $997.00 Price Target at Leerink Partners - Leerink Partners raised Regeneron’s price target from $835 to $997 while maintaining a “market perform”
More from 1 other outlet
Truist Securities maintains Regeneron Pharmaceuticals at Buy, raises price target to $982 from $780
TradingView Truist Securities maintained Regeneron Pharmaceuticals at Buy and raised its price target to $982 from $780, a 25.9% increase. The price target implies an upside of 5.8% from the Oct 30 cl
Wells Fargo maintains Regeneron Pharmaceuticals at Equal-Weight, raises price target to $925 from $750
TradingView Wells Fargo maintained Regeneron Pharmaceuticals at Equal-Weight and raised its price target to $925 from $750, a 23.3% increase. The price target is roughly in line with the Oct 30 clo
Analyst recommendations: Adobe, Caterpillar, Fair Isaac, Regeneron Pharmaceuticals…
Every morning, find a selection of analysts' recommendations covering North America. The list only includes companies that have received a rating or price target change, or new analyst coverage. It... -November 02, 2026 at 05:49 am EST -…
Regeneron Pharmaceuticals (REGN) share price
Regeneron Pharmaceuticals Inc Stock Price Live, Charts & News The Economic Times
[Regeneron Pharmaceuticals Q3 2026 Earnings Call] Regeneron Q3 revenue jumps 36% to $5.1B, EPS surges 70% as Dupixent, EYLEA HD, Libtayo hit records
Regeneron Pharmaceuticals delivered another standout quarter, with total revenue climbing 36% year-over-year to $5.1 billion and non-GAAP diluted EPS surging 70% to $20.07, driven by record sales of its key growth drivers—Dupixent, EYLEA…
REGENERON PHARMACEUTICALS ($REGN) Releases Q3 2026 Earnings
REGENERON PHARMACEUTICALS ($REGN) posted quarterly earnings results for Q3 2026 on Friday, October 30th. The company reported earnings of $20.07 per share, beating estimates of $16.48 by $3.59. The company also reported revenue of…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com22
- marketbeat.com20
- themarketsdaily.com12
- tradingview.com10
- defenseworld.net6
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 83 articles, not a forecast.